Literature DB >> 10569134

CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders.

A Younes1, A Carbone.   

Abstract

CD30 and CD40 are members of the tumor necrosis factor (TNF) receptor family. These two receptors have pleiotropic biologic functions including induction of apoptosis and enhancing cell survival. This review will discuss the pattern of expression of these receptors in malignant lymphoid disorders and their prospective ligands. Understanding issues related to these two ligands and their receptors in lymphoid malignancies may help to improve the classification of these diseases and could open the doors for new treatment strategies.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10569134     DOI： 10.1177/172460089901400303

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN： 0393-6155            Impact factor:   3.248


  9 in total

Review 1.  New molecular targets for treatment of lymphoma.

Authors:  Barbara Pro; Anas Younes
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

2.  Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.

Authors:  April Chiu; Weifeng Xu; Bing He; Stacey R Dillon; Jane A Gross; Eric Sievers; Xugang Qiao; Paul Santini; Elizabeth Hyjek; Joong-won Lee; Ethel Cesarman; Amy Chadburn; Daniel M Knowles; Andrea Cerutti
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

Review 3.  Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

Authors:  Adam Jona; Anas Younes
Journal:  Blood Rev       Date:  2010-09-15       Impact factor: 8.250

Review 4.  Role of CD30 targeting in malignant lymphoma.

Authors:  Anita Kumar; Anas Younes
Journal:  Curr Treat Options Oncol       Date:  2014-06

5.  Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Ther Adv Hematol       Date:  2012-08

Review 6.  Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review.

Authors:  Roberta Fedele; Massimo Martino; Anna Grazia Recchia; Giuseppe Irrera; Massimo Gentile; Fortunato Morabito
Journal:  J Immunol Res       Date:  2015-12-16       Impact factor: 4.818

Review 7.  Fate of Antibody-Drug Conjugates in Cancer Cells.

Authors:  Cécile Chalouni; Sophia Doll
Journal:  J Exp Clin Cancer Res       Date:  2018-02-06

8.  Two distinct signalling cascades target the NF-kappaB regulatory factor c-IAP1 for degradation.

Authors:  Rebecca A Csomos; Casey W Wright; Stefanie Galbán; Karolyn A Oetjen; Colin S Duckett
Journal:  Biochem J       Date:  2009-04-28       Impact factor: 3.857

Review 9.  Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Authors:  Xueyan Chen; Lorinda A Soma; Jonathan R Fromm
Journal:  Onco Targets Ther       Date:  2013-12-19       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.